TL;DR

•Some researchers argue that psychedelic-assisted therapy should not be automatically off limits for older adolescents with severe, treatment-resistant mental health conditions.

•The strongest evidence still comes from adult studies, not child or teen studies.

•Youth research needs extra safeguards because the teen brain, family context, consent process, and risk profile are different from adult care.

•Any future adolescent trials should include careful screening, family education, strong monitoring, and long-term follow-up.

•For families in Texas, today’s best step is not underground use, but informed conversation with qualified mental health and medical professionals. 

Should psychedelic-assisted therapy be off limits for kids and adolescents?

Psychedelic-assisted therapy should not be treated as a simple yes-or-no issue for young people. A 2026 review argues that carefully designed research may be ethical for some adolescents, especially when severe mental illness has not improved with standard care. But it also stresses that youth need stronger protections than adults (1).

This topic can make parents nervous, and for good reason. Psychedelics are powerful substances. Teenagers are still developing in body, brain, identity, and relationships. At the same time, many families are watching a child struggle with depression, anxiety, trauma, or suicidal thinking after several treatments have failed.

The real question is not whether teens should be given psychedelics casually. They should not. The better question is whether science can study these therapies in a safe, ethical way for carefully selected older adolescents.

Why are researchers even asking this question now?

Researchers are asking because youth mental health needs are high, while many current treatments do not help enough. Adult psychedelic therapy studies for depression, trauma, and anxiety have created interest, but teens have usually been excluded from modern trials because of ethical and legal concerns (2).

The 2026 article in the British Journal of Clinical Pharmacology notes that early youth research is limited, but it also points to possible benefits and possible risks. Young people may be more likely to have anxiety, challenging experiences, or ego dissolution during psychedelic states (1). That means any research must move slowly.

A 2025 scoping review in The Lancet Child & Adolescent Health found very little modern clinical trial evidence for participants under 18. The authors identified only a small number of trial plans or registrations, and no completed published trial findings for adolescents in the review period (2). 

What makes adolescent psychedelic research different from adult research?

Adolescent research is different because teens are still developing, depend on caregivers, and may have less ability to judge long-term risks. Consent is also more complex because both the young person and guardians may need to understand the study, its risks, and its limits.

A teen’s mental health symptoms also sit inside a family and school system. If a young person has trauma, conflict at home, bullying, substance use, or religious fear, the treatment plan cannot focus only on the dosing day. The support system matters before, during, and after any intervention.

Ethics experts have warned against assuming that adult safety data can simply be applied to teenagers (3). That caution is important. Adult trials often exclude people with certain risks. Teens may need even more careful screening for bipolar disorder, psychosis risk, suicidality, substance use, medical concerns, and family instability. 

What safeguards would ethical teen trials need?

Ethical teen trials would need strict screening, lower-risk dosing plans, intensive psychological support, family education, emergency procedures, and long-term follow-up. They would also need independent oversight and clear rules for stopping participation if risk increases.

Recent experts have suggested that older adolescents, such as ages 16 to 17, may be the most realistic group for early trials, and only when the condition is serious and treatment-resistant (4). Another 2026 framework calls for more psychological support, rigorous oversight, and youth-centered regulatory dialogue (5).

This means that “research access” is not the same thing as “open access.” A careful trial would be structured, monitored, and limited. It would not resemble a retreat, party, or underground session.

For Texas families, this distinction matters. If a teen is struggling with panic, depression, trauma symptoms, or suicidal thoughts, support should begin with established care such as anxiety therapy, therapy for depression, or PTSD counseling. 

What should parents do if their teen asks about psychedelics?

Parents should respond with calm curiosity, not panic or praise. Ask what your teen has heard, what problem they hope psychedelics would solve, and whether they are already using substances. Then involve qualified mental health or medical support if there is risk, secrecy, or serious distress.

Many teens hear about psychedelics online before they hear balanced information from adults. If a parent reacts with shame, the teen may hide more. If a parent reacts with excitement, the teen may underestimate the risks. The middle path is honest conversation.

You might say, “I understand why you are curious, especially if you feel stuck. I also want us to be careful because your brain and your safety matter.” That kind of response keeps the door open while setting a clear limit.

If your family is dealing with trauma, depression, or fear after substance use, Jeff can help you think through the next step. A consultation can focus on safety, communication, and what kind of therapy is appropriate now, without assuming psychedelic treatment is the answer. 

Could psychedelic therapy ever help young people with trauma or depression?

It is possible that future research may find a role for psychedelic-assisted therapy in some older adolescents with severe depression, PTSD, or anxiety. But the evidence is not strong enough today to treat it as an established youth treatment.

The best adult psychedelic studies include preparation, monitored dosing, and integration therapy. They do not just give a drug and hope for the best. If adolescent research moves forward, it will need even more support because young people are still building identity, coping skills, and trust in adults.

Serenity has written about the link between developmental trauma and psychedelic work in Psychedelic Therapy and Trauma: What You Need to Know About Childhood Experiences. That article is useful because many adult questions about psychedelic therapy begin with pain that started early in life. 

What is the safest takeaway for families right now?

The safest takeaway is that adolescent psychedelic therapy is a research question, not a do-it-yourself treatment plan. Families should avoid underground use and seek licensed support for anxiety, depression, trauma, or substance use while science studies whether these therapies can be safe for youth.

If you are a parent, you may feel torn. You may want hope for your child, but you may also feel afraid of hype, risk, and online misinformation. That tension is understandable.

Jeff Jones, LPC, offers trauma-informed counseling, psychedelic integration for adults, and harm-reduction-informed conversations for families navigating these questions. If you want help thinking through what this research does and does not mean for your situation, schedule a free consultation with Jeff Jones, LPC

About the Author

This article was written by Jeff Jones, a Licensed Professional Counselor (LPC) in Texas in practice since 1999. He is a 2024 graduate of the CIIS Center for Psychedelic Therapies and Research program. With a compassionate and evidence-based approach, he helps clients navigate life's challenges and find a path toward healing.

Disclaimer

The information in this article, including discussions of psychedelic-assisted psychotherapy, is for informational purposes only. Psychedelic-assisted psychotherapy has not been approved by all regulatory agencies in the United States, and its safety and efficacy are still being established. This content is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

1.Hearn, B. G., et al. (2026). Exploring new avenues: Psychedelic-assisted therapy for young people. British Journal of Clinical Pharmacology. https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1002/bcp.70579

2. Rajwani, K., et al. (2025 ). Clinical psychedelic research in adolescents: A scoping review and overview of ethical considerations. The Lancet Child & Adolescent Health. https://isps.yale.edu/research/publications/isps25-56

3.Becker, T. D., et al. (2025). Psychedelic therapeutics for adolescents: Ethics, safety, opportunities, and equipoise. Journal of the American Academy of Child & Adolescent Psychiatry. https://pubmed.ncbi.nlm.nih.gov/39709007/

4.Jeffrey, J K., et al. (2024 ). Clinical research trials of psychedelic-assisted therapy in adolescents aged 16 to 17 years: Rationale balanced with caution. Journal of the American Academy of Child & Adolescent Psychiatry. https://pubmed.ncbi.nlm.nih.gov/38734406/

5.Wilens, T. E., et al. (2026). Toward a framework for psychedelic clinical trials in adolescents. Child and Adolescent Psychiatry and Mental Health. https://link.springer.com/article/10.1186/s13034-026-01064-x